Statement of Need

Prostate cancer is the second leading cause of death from cancer in men in the United States. Outcomes are worse for Black men who are 70% more likely to develop prostate cancer, twice as likely to die from the disease, and for whom advanced metastatic prostate cancer occurs at a 4:1 ratio compared to white men of European ancestry. Current evidence suggests that there is a significant gap in treatment rates between Black and white men. Studies show that African American and Hispanic men have significant disparity in the receipt of definitive therapy compared to Caucasian men, and higher tumor grade was associated with decreasing odds of definitive therapy for these populations. While the etiology for these racial differences in the clinical behavior of prostate cancer is largely unknown, hormonal, nutritional, genetic, behavioral, and socioeconomic factors have all been implicated. Providers must be aware of disparities faced by specific patient population and implement processes to routinely assess needs and barriers across the disease course, providers, and healthcare systems.

Target Audience

This program is intended for medical oncologists, urologists, pathologists, nurse practitioners, physician assistants, oncology pharmacists, nurse navigators and other members of the multidisciplinary team who care for patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Introduce strategies to reduce the median time to treatment for diverse patients with mCRPC
• Optimally select targeted therapies in the advanced prostate cancer setting considerate of patient- and disease-related factors
• Identify patients with mCRPC who may be eligible for a clinical trial
• Apply tactics to improve care coordination, access to care, and SDM for Black men with mCRPC

Method of Participation

To receive credit, learners are required to complete a baseline assessment; design, develop, and implement an action plan using our automated platform; view the online interventions; and return after 30 days to report progress in making system-level changes. A thorough response to the reflection questionnaire on your involvement in the quality improvement activity is also required for meaningful participation. A certificate will be available upon completion of the reflection questionnaire. There is no fee to participate in the activity or for the generation of the certificate.

ABIM credit will be submitted to ABIM within 30 days of completion. CPE credit will be submitted to CPE Monitor^® on the first business day of each month. Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit.

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Accreditation and Credit Designation Statement

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS on the first day of each month.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS on the first day of each month.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Disclosures

As providers accredited by the ACCME, The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) ask everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine and ACHL require authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

The following financial relationships have been provided:

Russell Z. Szmulewitz, MD
Advisor: Bayer, Novartis, Pfizer, Johnson & Johnson.
Research Funding (Institution): Abbvie, Bayer, Janus, Merck, Novartis, Nurix, Pfizer

Samuel L. Washington III, MD, MAS
No financial relationships to disclose.

Meghan Catenacci, BSN, RN, MS
Consultant: Novartis

Timothy McNichol, LCSW
No financial relationships to disclose.

Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose.

Staff and Reviewer Disclosures

The University of Chicago Pritzker School of Medicine, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of any publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: None

Acknowledgement

Provided by University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

This is supported by educational grants from Astellas and Pfizer Inc., Bayer HealthCare Pharmaceuticals Inc, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.